📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
Human PK Predictions & DMPK in Lead Optimisation
Human PK predictions are a key element of any integrated drug discovery process: if…
Blog
Preventing Costly Delays: Accessing Drug Formulation Expertise Early
Don't delay or ignore the solid form aspects and risk the problem of unusual results from studies. Learn more about drug formulation here.
Blog
Effective drug design: insights from DMPK
Modelling and simulation approaches developed under the DMPK umbrella utilising animal in vivo data and…
Blog
Cancer Survivorship, at What Cost?
Sunday 4th of June is World Cancer Survivor Day 2023, a day dedicated to those who have survived a cancer diagnosis.  But importantly, the day is also designed to raise awareness of the often-overlooked challenges that this survivorship brings.
News
Sygnature Discovery launches its in vivo LPS model to ​p​​rofile early-stage anti-inflammatory drugs​
Sygnature Discovery has ​established an in vivo ​…
Blog
To follow or not to follow (that is the question)
There are many terms – not all of them complimentary – used to describe…
Journal Papers
Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation
Norbert Minet, Anne-Claire Boschat, Rebecca Lane, David Laughton, Philip Beer, Hélène Asnagli, Claire Soudais, Tim Bourne, Alain Fischer, Emmanuel Martin, Sylvain Latour  Abstract The CTP…
Blog
Tricks for Old Targets and Challenges of Molecular Glues: AACR Reflections
Sygnature Discovery's oncology team reflect on recent developments in oncology drug discovery presented at this year's AACR meeting.
Blog
Unravelling the Intricacies of Neuroinflammation: A Closer Look into the Brain’s Immune Response
The human brain, an amazing organ, is responsible for controlling how we feel, what we…
Blog
Hit Validation for Suspicious Minds
Regardless of the target or modality, all drug discovery programmes commence with some form of…
Journal Papers
Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex
Maxim A X Tollenaere, Christina Mølck, Ian Henderson, Scott Pollack, Philip Addis, Helle Heibroch Petersen, Hanne Norsgaard Abstract Tralokinumab, a fully…
Journal Papers
The severity of SARS-CoV-2 infection in K18-hACE2 mice is attenuated by a novel steroid-derivative in a gender-specific manner
Sachin A Gupte, Chandra Shekhar Bakshi, Emma Blackham, Gerald E Duhamel, Allan Jordan, Padmini Salgame, Melinee D’silva, Mohammad Y Khan, Jerry Nadler, Rakhee Gupte…
Blog
The Dark Art of Chemistry: Chiral Chromatography
Explore the Significance of Chiral Chromatography in Enantiomer Separation: An In-Depth Analysis by Alex Brien, Senior Principal Scientist of Analytical Chemistry at Sygnature Discovery.
News
Sygnature Discovery accelerates global growth with major North American acquisition
Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of…
Journal Papers
A Comparative Study on the Lysosomal Cation Channel TMEM175 Using Automated Whole-Cell Patch-Clamp, Lysosomal Patch-Clamp, and Solid Supported Membrane-Based Electrophysiology: Functional Characterization and High-Throughput Screening Assay Development
Andre Bazzone, Maria Barthmes, Cecilia George, Nina Brinkwirth, Rocco Zerlotti, Valentin Prinz, Kim Cole,…
Blog
Bioavailability – can we improve it?
Bioavailability: What is it and what factors influence it?  Bioavailability (F) is a…
News
Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment
Sygnature Discovery is delighted to announce that its customer, River BioMedics, has raised an…
News
Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds
Blog
Stuck on You: Discovering Covalent Therapeutics with Biophysics
Dive into the world of covalent therapeutics and their promising benefits in drug development. Discover how biophysics helps us unravel their complexities and optimize their effectiveness in innovative treatments.
News
Sygnature Discovery collaborates with Axol Bioscience to utilize ​human ​iPSC-derived microglial cells in high-content imaging drug discovery screening workflows.
On 10th October 2023, Sygnature Discovery, a world-leading integrated drug discovery provider and…
Blog
The Importance of Counter Screens in HTS
Unlock the full potential of High-Throughput Screening (HTS) with strategic counter screens. Discover when and how to apply them effectively, ensuring precise compound selection and optimizing your drug discovery projects for success.
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch